Natus Medical Incorporated Defends Against Ceribell's Complaint, Preserving Competition in the EEG Market and Improving Patient Care

Strategic Insights -

Natus Medical Incorporated, a leading solution source for healthcare providers to screen, diagnose, and treat disorders affecting the brain and neural pathways, has filed its response to Ceribell's complaint alleging patent infringement. The complaint, filed with the U.S. International Trade Commission, alleges violations of section 337 of the Tariff Act of 1930. Natus's response follows Ceribell's request to the USITC to investigate its allegations, seeking to prevent continued sales of Natus's latest commercialized innovation, BrainWatch, in the U.S. marketplace.

BrainWatch is a point-of-care EEG solution designed to bring real-time seizure detection to hospitals nationwide. The system seamlessly integrates neurology workflows through Natus's NeuroWorks system, opening the channel for patients to receive neurological care immediately following use. With its ease of use and seamless integration, neurologists can welcome BrainWatch technology into their hospitals, supporting easily translatable studies that aid in insurance reimbursement for hospitals and patients.

"We are confident that healthy competition in this market will ensure that patients receive the most innovative, sophisticated technology available to them," said Natus CEO Chris Landon. "Patient and doctor choice will remain our top priority as we continue to defend ourselves against Ceribell's allegations."

Key Takeaways:

  • Natus has filed its response to Ceribell's complaint, denying patent infringement and any "copying" of Ceribell's product.
  • BrainWatch, Natus's latest commercialized innovation, is a point-of-care EEG solution designed to bring real-time seizure detection to hospitals nationwide.
  • The system seamlessly integrates neurology workflows through Natus's NeuroWorks system, opening the channel for patients to receive neurological care immediately following use.
  • Ceribell is a Chinese investment firm-backed entrant into the EEG market, whose headband is manufactured in China and Vietnam.
  • Natus maintains its confidence that the Company's BrainWatch system has the potential to significantly impact patient care and improve clinical and economic outcomes both in the ER and ICU.
  • Natus urges and will continue to argue to the USITC that any restriction on the ability of Natus to sell BrainWatch in the U.S. will prevent access to care that Natus can provide to patients.

Statistics:

  • The brain and neural pathways affect 85 million adults in the United States, with the disorders often going undiagnosed for years.
  • BrainWatch is the first point-of-care EEG solution that seamlessly integrates neurology workflows through the Company's NeuroWorks system.
  • BrainWatch represents the only point-of-care EEG solution that provides real-time seizure detection to hospitals nationwide.
  • Ceribell's headband is manufactured in China and Vietnam.

Sources:

  • Natus Medical Incorporated
  • U.S. International Trade Commission
  • Prosek Partners for Natus